Ignite Creation Date:
2024-05-05 @ 4:57 PM
Last Modification Date:
2024-10-26 @ 9:26 AM
Study NCT ID:
NCT00357760
Status:
COMPLETED
Last Update Posted:
2017-06-23
First Post:
2006-07-26
Brief Title:
Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer
Sponsor:
National Cancer Institute NCI
Organization:
National Cancer Institute NCI
Study Overview
Official Title:
A Randomized Phase II Study to Determine the Effect of 2 Different Doses of AVE0005 VEGF Trap in Patients With Metastatic Renal Cell Carcinoma
Status:
COMPLETED
Status Verified Date:
2017-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This randomized phase II trial studies how well ziv-aflibercept VEGF Trap works in treating patients with kidney cancer that has spread from the primary site to other places in the body metastatic or is unable to be removed with surgery unresectable Ziv-aflibercept may stop the growth of kidney cancer by blocking blood flow to the tumor
Detailed Description:
PRIMARY OBJECTIVE
I To determine the effect of two different doses of AVE0005 vascular endothelial growth factor VEGF Trap ziv-aflibercept treatment on the progression-free proportion at 8 weeks in patients with metastatic renal cell carcinoma who had previous treatment with a tyrosine kinase inhibitor TKI
SECONDARY OBJECTIVES
I To determine the effect of AVE0005 VEGF Trap treatment on objective response rate in patients with metastatic renal cell carcinoma who have had previous TKI treatment
II To describe progression-free survival among patients who undergo dose escalation following progression on low-dose AVE0005 VEGF Trap
III To evaluate the safety and tolerability of AVE0005 VEGF Trap in patients with metastatic renal cell carcinoma who have had previous treatment with a TKI
OTHER PRE-SPECIFIED OBJECTIVES
I To determine the circulating levels of VEGF AVE0005 VEGF-Trap complex and correlate it with clinical activity
II To evaluate the modulation of specific angiogenesis-related protein expression by AVE0005 VEGF Trap
OUTLINE Patients are randomized to 1 of 2 treatment arms
ARM A Higher dose of VEGF Trap Patients receive a higher dose of ziv-aflibercept intervenously IV over 1 hour on day 1
ARM B Lower dose of VEGF Trap Patients receive a lower dose of ziv-aflibercept IV over 1 hour on day 1
In both arms courses repeat every 14 days in the absence of disease progression or unacceptable toxicity Patients receiving treatment on Arm B may crossover and receive treatment on Arm A at the time of disease progression
After completion of study treatment patients are followed every 3 months for 2 years and then every 6 months for 1 year
I To determine the effect of two different doses of AVE0005 vascular endothelial growth factor VEGF Trap ziv-aflibercept treatment on the progression-free proportion at 8 weeks in patients with metastatic renal cell carcinoma who had previous treatment with a tyrosine kinase inhibitor TKI
SECONDARY OBJECTIVES
I To determine the effect of AVE0005 VEGF Trap treatment on objective response rate in patients with metastatic renal cell carcinoma who have had previous TKI treatment
II To describe progression-free survival among patients who undergo dose escalation following progression on low-dose AVE0005 VEGF Trap
III To evaluate the safety and tolerability of AVE0005 VEGF Trap in patients with metastatic renal cell carcinoma who have had previous treatment with a TKI
OTHER PRE-SPECIFIED OBJECTIVES
I To determine the circulating levels of VEGF AVE0005 VEGF-Trap complex and correlate it with clinical activity
II To evaluate the modulation of specific angiogenesis-related protein expression by AVE0005 VEGF Trap
OUTLINE Patients are randomized to 1 of 2 treatment arms
ARM A Higher dose of VEGF Trap Patients receive a higher dose of ziv-aflibercept intervenously IV over 1 hour on day 1
ARM B Lower dose of VEGF Trap Patients receive a lower dose of ziv-aflibercept IV over 1 hour on day 1
In both arms courses repeat every 14 days in the absence of disease progression or unacceptable toxicity Patients receiving treatment on Arm B may crossover and receive treatment on Arm A at the time of disease progression
After completion of study treatment patients are followed every 3 months for 2 years and then every 6 months for 1 year
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| U10CA021115 | NIH | ECOG-ACRIN Cancer Research Group | httpsreporternihgovquickSearchU10CA021115 |
| NCI-2009-00559 | REGISTRY | None | None |
| E4805 | OTHER | None | None |
| U10CA180820 | NIH | None | None |